Phebra SODIUM BICARBONATE 8.4% w/v 8.4 g/100 mL injection BP vial Australia - English - Department of Health (Therapeutic Goods Administration)

phebra sodium bicarbonate 8.4% w/v 8.4 g/100 ml injection bp vial

phebra pty ltd - sodium bicarbonate, quantity: 84 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - sodium bicarbonate injection is indicated as an alkalinising agent in the treatment of metabolic acidosis which may occur in many conditions including diabetes, starvation, hepatitis, cardiac arrest, shock, severe dehydration, renal insufficiency, severe diarrhoea, addison's disease or administration of acidifying salts (e.g. excessive sodium chloride, calcium chloride, ammonium chloride). sodium bicarbonate injection is also used to increase urinary ph in order to increase the solubility of certain weak acids (e.g. cystine, sulphonamides, uric acid) and in the treatment of certain intoxications (e.g. methanol, phenobarbitone, salicylates, lithium) to decrease renal absorption of the drug or to correct acidosis.

Phebra SODIUM CHLORIDE 0.9% 900 mg in 100 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

phebra sodium chloride 0.9% 900 mg in 100 ml solution for injection vial

phebra pty ltd - sodium chloride, quantity: 9 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 01 jan 1991 : prophylaxis of heat prostration or muscle cramps, chloride deficiency due to diuresis or salt restriction, prevention or treatment of extracellular volume depletion. parenteral - 0.9% (isotonic) nacl is used to restore sodium and chloride losses; to dilute or dissolve drugs for iv, im or sc use, flushing of iv catheters; extracellular fluid replacement; priming solution for hemodialysis; initiate and terminate blood transfusions so red blood cells will not hemolyze; metabolic alkalosis when there is fluid loss and mild sodium depletion. topical or irrigation - relief of inflamed, dry or crusted nasal membranes or as a topical irrigating or flush solution.

Phebra SODIUM CHLORIDE 23.4% 2.34 g in 10 mL concentrated  injection for infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

phebra sodium chloride 23.4% 2.34 g in 10 ml concentrated injection for infusion vial

phebra pty ltd - sodium chloride, quantity: 234 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 01 january 1991 : as an additive to parenteral fluids in patients who have specific electrolyte needs for sodium or chloride ions. as a sclerosing agent for small symptomatic varicose veins.

PHEBRA SODIUM CHLORIDE 0.9% (450mg/50mL) injection BP vial Australia - English - Department of Health (Therapeutic Goods Administration)

phebra sodium chloride 0.9% (450mg/50ml) injection bp vial

phebra pty ltd - sodium chloride, quantity: 9 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 01 jan 1991 : normal saline can be used as the vehicle for many parenteral drugs and as an electrolyte replenisher for maintenance or replacement of deficits of extracellular fluid. it can also be used as a sterile irrigation medium.

Phebra METHYLENE BLUE 50 mg/5 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

phebra methylene blue 50 mg/5 ml injection vial

phebra pty ltd - methylene blue, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - methylene blue injection usp is indicated: for the treatment of drug-induced methaemoglobinaemia; for the treatment of idiopathic methaemoglobinaemia (in which structural abnormality of haemoglobin is not present); as a bacteriological strain as a dye in diagnostic procedures such as fistula detection; for the delineation of certain body tissues during surgery.

Phebra MAGNESIUM SULFATE HEPTAHYDRATE 50% 5g/10mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

phebra magnesium sulfate heptahydrate 50% 5g/10ml injection vial

phebra pty ltd - magnesium sulfate heptahydrate, quantity: 500 mg/ml - injection, concentrated - excipient ingredients: water for injections - parenteral administration of magnesium is indicated in the treatment of acute hypomagnesaemia. magnesium salts are also indicated to prevent hypomagnesaemia in patients receiving total parenteral nutrition. magnesium sulphate is also indicated in the prevention and treatment of life-threatening seizures in the treatment of toxemias of pregnancy (pre-eclampsia and eclampsia). for emegency treatment of some arrhythmias such as torsade de pointes and those associated with hypokalemia.

PHEBRA PARALDEHYDE paraldehyde 5mL injection BP Australia - English - Department of Health (Therapeutic Goods Administration)

phebra paraldehyde paraldehyde 5ml injection bp

phebra pty ltd - paraldehyde, quantity: 5 ml - injection, solution - excipient ingredients: hydroquinone - paraldehyde has been used as a sedative and hypnotic in a variety of clinical situations, although it has been largely replaced by safer and/or more effective agents. it may also be used in the treatment of convulsive episodes arising from tetanus, status epilepticus and poisoning by convulsive drugs, when other agents are inappropriate or ineffective. paraldehyde may be effective in reducing the anxiety associated with withdrawal from drugs such as narcotics or barbiturates, as well as in the management of acute agitation or delirium tremens due to alcohol withdrawal. paraldehyde is only recommended for use in these conditions when other treatments are ineffective or deemed inappropriate.

Phebra CALCIUM CHLORIDE DIHYDRATE 10% 1 g/10 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

phebra calcium chloride dihydrate 10% 1 g/10 ml injection vial

phebra pty ltd - calcium chloride dihydrate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - parental administration of calcium is indicated in the treatment of hypocalcaemia where rapid increase in plasma calcium is required, such as in hypocalcaemic tetany and tetany due to parathyroid deficiency. intravenous calcium is also indicated to antagonise the cardiotoxicity of hyperkalaemia.

Phebra SODIUM BICARBONATE 8.4% w/v 840 mg/10 mL injection BP vial Australia - English - Department of Health (Therapeutic Goods Administration)

phebra sodium bicarbonate 8.4% w/v 840 mg/10 ml injection bp vial

phebra pty ltd - sodium bicarbonate, quantity: 84 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - sodium bicarbonate injection is indicated as an alkalinising agent in the treatment of metabolic acidosis which may occur in many conditions including diabetes, starvation, hepatitis, cardiac arrest, shock, severe dehydration, renal insufficiency, severe diarrhoea, addison's disease or administration of acidifying salts (e.g. excessive sodium chloride, calcium chloride, ammonium chloride). sodium bicarbonate injection is also used to increase urinary ph in order to increase the solubility of certain weak acids (e.g. cystine, sulphonamides, uric acid) and in the treatment of certain intoxications (e.g. methanol, phenobarbitone, salicylates, lithium) to decrease renal absorption of the drug or to correct acidosis.

PHEBRA NAPROXEN SUSPENSION naproxen 125mg/5mL oral liquid bottle Australia - English - Department of Health (Therapeutic Goods Administration)

phebra naproxen suspension naproxen 125mg/5ml oral liquid bottle

phebra pty ltd - naproxen, quantity: 25 mg/ml - oral liquid, suspension - excipient ingredients: sorbitol solution (70 per cent) (crystallising); aluminium magnesium silicate; purified water; sucrose; sodium chloride; fumaric acid; methyl hydroxybenzoate; sunset yellow fcf; sodium hydroxide; flavour - treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, for the symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.